Overview

Bioequivalence of Telmisartan/Amlodipine Fixed Dose Combination Compared With Its Monocomponents in Healthy Male and Female Volunteers

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To demonstrate the bioequivalence of 80 mg telmisartan / 10 mg amlodipine fixed dose combination (FDC) vs. its monocomponents
Phase:
Phase 1
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Amlodipine
Telmisartan
Telmisartan amlodipine combination